Cargando…
Co-prescription of Dual-Antiplatelet Therapy and Proton Pump Inhibitors: Current Guidelines
Dual-antiplatelet therapy (DAPT) prevents thrombotic complications associated with coronary artery disease, acute coronary syndrome, and stent thrombosis following the percutaneous coronary intervention or coronary artery bypass grafting. When initiating DAPT, the risk of thrombosis must be balanced...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901154/ https://www.ncbi.nlm.nih.gov/pubmed/35273851 http://dx.doi.org/10.7759/cureus.21885 |
_version_ | 1784664296436793344 |
---|---|
author | Saven, Hannah Zhong, Lynna McFarlane, Isabel M |
author_facet | Saven, Hannah Zhong, Lynna McFarlane, Isabel M |
author_sort | Saven, Hannah |
collection | PubMed |
description | Dual-antiplatelet therapy (DAPT) prevents thrombotic complications associated with coronary artery disease, acute coronary syndrome, and stent thrombosis following the percutaneous coronary intervention or coronary artery bypass grafting. When initiating DAPT, the risk of thrombosis must be balanced with the increased risk of upper gastrointestinal bleed (UGIB). Proton-pump inhibitors (PPIs) are concurrently prescribed with DAPT to reduce bleeding risk. In this review, we discuss the benefits and potential complications of DAPT/PPI co-prescription. The only large international randomized control trial (RCT), Clopidogrel and the Optimization of Gastrointestinal Events Trial (COGENT), shows robust evidence that PPIs are a safe and effective method to reduce the risk of bleeding in patients on DAPT. However, more large-scale RCTs are needed to study potential long-term effects and draw a stronger conclusion on this topic. |
format | Online Article Text |
id | pubmed-8901154 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-89011542022-03-09 Co-prescription of Dual-Antiplatelet Therapy and Proton Pump Inhibitors: Current Guidelines Saven, Hannah Zhong, Lynna McFarlane, Isabel M Cureus Cardiology Dual-antiplatelet therapy (DAPT) prevents thrombotic complications associated with coronary artery disease, acute coronary syndrome, and stent thrombosis following the percutaneous coronary intervention or coronary artery bypass grafting. When initiating DAPT, the risk of thrombosis must be balanced with the increased risk of upper gastrointestinal bleed (UGIB). Proton-pump inhibitors (PPIs) are concurrently prescribed with DAPT to reduce bleeding risk. In this review, we discuss the benefits and potential complications of DAPT/PPI co-prescription. The only large international randomized control trial (RCT), Clopidogrel and the Optimization of Gastrointestinal Events Trial (COGENT), shows robust evidence that PPIs are a safe and effective method to reduce the risk of bleeding in patients on DAPT. However, more large-scale RCTs are needed to study potential long-term effects and draw a stronger conclusion on this topic. Cureus 2022-02-03 /pmc/articles/PMC8901154/ /pubmed/35273851 http://dx.doi.org/10.7759/cureus.21885 Text en Copyright © 2022, Saven et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Cardiology Saven, Hannah Zhong, Lynna McFarlane, Isabel M Co-prescription of Dual-Antiplatelet Therapy and Proton Pump Inhibitors: Current Guidelines |
title | Co-prescription of Dual-Antiplatelet Therapy and Proton Pump Inhibitors: Current Guidelines |
title_full | Co-prescription of Dual-Antiplatelet Therapy and Proton Pump Inhibitors: Current Guidelines |
title_fullStr | Co-prescription of Dual-Antiplatelet Therapy and Proton Pump Inhibitors: Current Guidelines |
title_full_unstemmed | Co-prescription of Dual-Antiplatelet Therapy and Proton Pump Inhibitors: Current Guidelines |
title_short | Co-prescription of Dual-Antiplatelet Therapy and Proton Pump Inhibitors: Current Guidelines |
title_sort | co-prescription of dual-antiplatelet therapy and proton pump inhibitors: current guidelines |
topic | Cardiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901154/ https://www.ncbi.nlm.nih.gov/pubmed/35273851 http://dx.doi.org/10.7759/cureus.21885 |
work_keys_str_mv | AT savenhannah coprescriptionofdualantiplatelettherapyandprotonpumpinhibitorscurrentguidelines AT zhonglynna coprescriptionofdualantiplatelettherapyandprotonpumpinhibitorscurrentguidelines AT mcfarlaneisabelm coprescriptionofdualantiplatelettherapyandprotonpumpinhibitorscurrentguidelines |